Tokyo Tape
Sign in
← PeptiDream

Quarterly report · Q2

4587.TEDINET S100OZ1E
Period2022-01-01 → 2022-06-30
Filed2022-08-10
StandardIFRS
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 65
MetricValuePeriodScopeSource row
Revenue¥5.0bn2022-01-01 → 2022-06-30Cons.Revenue IFRS
Revenue¥4.6bn2022-04-01 → 2022-06-30dCons.Revenue IFRS
Revenue¥9.4bn2021-01-01 → 2021-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥2.9bn2021-01-01 → 2021-06-30Cons.Revenue IFRS
Revenue¥1.4bn2021-04-01 → 2021-06-30dCons.Revenue IFRS
Operating income−¥1.6bn2022-01-01 → 2022-06-30Cons.Operating profit loss IFRS
Operating income−¥393m2022-04-01 → 2022-06-30dCons.Operating profit loss IFRS
Operating income¥436m2021-01-01 → 2021-06-30Cons.Operating profit loss IFRS
Operating income¥442m2021-04-01 → 2021-06-30dCons.Operating profit loss IFRS
Profit before tax−¥1.5bn2022-01-01 → 2022-06-30Cons.Profit loss before tax IFRS
Profit before tax−¥361m2022-04-01 → 2022-06-30dCons.Profit loss before tax IFRS
Profit before tax¥3.8bn2021-01-01 → 2021-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥312m2021-01-01 → 2021-06-30Cons.Profit loss before tax IFRS
Profit before tax¥352m2021-04-01 → 2021-06-30dCons.Profit loss before tax IFRS
Net income (owners)−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥227m2022-04-01 → 2022-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥8m2021-01-01 → 2021-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥213m2021-04-01 → 2021-06-30dCons.Profit loss attributable to owners of parent IFRS
Net income−¥1.1bn2022-01-01 → 2022-06-30Cons.Profit loss IFRS
Net income−¥227m2022-04-01 → 2022-06-30dCons.Profit loss IFRS
Net income¥2.6bn2021-01-01 → 2021-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥8m2021-01-01 → 2021-06-30Cons.Profit loss IFRS
Net income¥213m2021-04-01 → 2021-06-30dCons.Profit loss IFRS
Total assets¥51.9bnat 2022-06-30Cons.Assets IFRS
Total assets¥27.0bnat 2021-12-31Cons.Assets IFRS
Total assets¥24.8bnat 2021-06-30Cons.Total assets IFRS (5-year summary)
Total assets¥26.1bnat 2020-12-31dCons.Assets IFRS
Total liabilities¥27.2bnat 2022-06-30Cons.Liabilities IFRS
Total liabilities¥1.7bnat 2021-12-31Cons.Liabilities IFRS
Total liabilities¥4.9bnat 2020-12-31dCons.Liabilities IFRS
Net assets / equity¥24.7bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥25.4bnat 2021-12-31Cons.Equity IFRS
Net assets / equity¥22.6bnat 2021-06-30Cons.Equity IFRS
Net assets / equity¥21.3bnat 2020-12-31dCons.Equity IFRS
Equity (owners)¥24.7bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥25.4bnat 2021-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥22.6bnat 2021-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)¥21.3bnat 2020-12-31dCons.Equity attributable to owners of parent IFRS
Cash & equivalents¥6.4bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.7bnat 2021-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.8bnat 2021-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥7.1bnat 2020-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥10m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥6.7bn2021-01-01 → 2021-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥5.0bn2021-01-01 → 2021-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥26.7bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥2.3bn2021-01-01 → 2021-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥450m2021-01-01 → 2021-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥21.6bn2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥66m2021-01-01 → 2021-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥45m2021-01-01 → 2021-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-8.132022-01-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-1.752022-04-01 → 2022-06-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥19.962021-01-01 → 2021-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-0.072021-01-01 → 2021-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥1.662021-04-01 → 2021-06-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥-8.132022-01-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-1.752022-04-01 → 2022-06-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥19.812021-01-01 → 2021-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-0.072021-01-01 → 2021-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥1.642021-04-01 → 2021-06-30dCons.Diluted earnings loss per share IFRS
Equity ratio47.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio93.8%at 2021-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio91.3%at 2021-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 9
SegmentItemPeriodValue
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.1bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.4bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥3.9bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥198m
—segment totalrevenue2022-01-01 → 2022-06-30¥5.0bn
—segment totalrevenue external2022-01-01 → 2022-06-30¥5.0bn
—segment totalsegment profit2022-01-01 → 2022-06-30−¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 668
ItemContextValueUnit
Equity IFRSCurrentQuarterInstant_RetainedEarningsIFRSMember15316606000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember1621761000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember24739352000JPY
Equity IFRSCurrentQuarterInstant24739352000JPY
Profit loss before tax IFRSPrior1YTDDuration312177000JPY
Profit loss before tax IFRSCurrentYTDDuration-1484964000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration305498000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration746539000JPY
Interest and dividend income ope cf IFRSPrior1YTDDuration-175000JPY
Interest and dividend income ope cf IFRSCurrentYTDDuration-1049000JPY
Interest expenses ope cf IFRSPrior1YTDDuration－JPY
Interest expenses ope cf IFRSCurrentYTDDuration66104000JPY
Foreign exchange loss gain ope cf IFRSPrior1YTDDuration-75987000JPY
Foreign exchange loss gain ope cf IFRSCurrentYTDDuration241433000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSPrior1YTDDuration359567000JPY
Share of loss profit of investments accounted for using equity method ope cf IFRSCurrentYTDDuration109972000JPY
Decrease increase in trade and other receivables ope cf IFRSPrior1YTDDuration7285072000JPY
Decrease increase in trade and other receivables ope cf IFRSCurrentYTDDuration-135091000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-171382000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-275141000JPY
Increase decrease in trade and other payables ope cf IFRSPrior1YTDDuration-1643432000JPY
Increase decrease in trade and other payables ope cf IFRSCurrentYTDDuration597710000JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSPrior1YTDDuration－JPY
Increase or decrease in retirement benefit asset or liability ope cf IFRSCurrentYTDDuration80852000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration174168000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration139828000JPY
Subtotal ope cf IFRSPrior1YTDDuration6545505000JPY
Subtotal ope cf IFRSCurrentYTDDuration86193000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration175000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration1049000JPY
Interest paid ope cf IFRSPrior1YTDDuration－JPY
Interest paid ope cf IFRSCurrentYTDDuration-51805000JPY
Income taxes paid ope cf IFRSPrior1YTDDuration-1586809000JPY
Income taxes paid ope cf IFRSCurrentYTDDuration-56233000JPY
Income taxes refund ope cf IFRSPrior1YTDDuration131000JPY
Income taxes refund ope cf IFRSCurrentYTDDuration10958000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration4959002000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration-9837000JPY
Proceeds from sale of marketable securities inv cf IFRSPrior1YTDDuration145222000JPY
Proceeds from sale of marketable securities inv cf IFRSCurrentYTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSPrior1YTDDuration－JPY
Payments for acquisition of subsidiaries inv cf IFRSCurrentYTDDuration-23460335000JPY
Loan advances to subsidiaries and associates inv cf IFRSPrior1YTDDuration-414097000JPY
Loan advances to subsidiaries and associates inv cf IFRSCurrentYTDDuration－JPY
Collection of loans receivable inv cf IFRSPrior1YTDDuration3120000JPY
Collection of loans receivable inv cf IFRSCurrentYTDDuration65926000JPY
Grant amount received inv cf IFRSPrior1YTDDuration136323000JPY
Grant amount received inv cf IFRSCurrentYTDDuration－JPY
Purchase of property plant and equipment inv cf IFRSPrior1YTDDuration-316109000JPY
Purchase of property plant and equipment inv cf IFRSCurrentYTDDuration-3218559000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 17 of 17 passed
balance sheet identityconsolidated 2020-12-31pass
balance sheet identityconsolidated 2021-12-31pass rounding
balance sheet identityconsolidated 2022-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-01-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2021-01-01/2021-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2021-01-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-12-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass